1h Free Analyst Time
The PARP (Poly ADP-ribose Polymerase) inhibitors market is forecasted to grow by USD 5555.99 mn during 2023-2028, accelerating at a CAGR of 13.25% during the forecast period. The report on the PARP (Poly ADP-ribose Polymerase) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the expanded application of PARP inhibitors, ease of administration for treatment of various cancer indications, and increasing patient assistance programs.
The PARP (Poly ADP-ribose Polymerase) inhibitors market is segmented as below:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies
- Online pharmacies
By End-user
- Ovarian cancer
- Breast cancer
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the PARP (Poly ADP-ribose Polymerase) inhibitors market covers the following areas:
- Parp (Poly ADP-ribose Polymerase) inhibitors market sizing
- Parp (Poly ADP-ribose Polymerase) inhibitors market forecast
- Parp (Poly ADP-ribose Polymerase) inhibitors market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Market Segmentation by End-user
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global PARP (Poly ADP-ribose Polymerase) inhibitors market: AbbVie Inc., Allarity Therapeutics Inc., Artios Pharma, AstraZeneca Plc, Bayer AG, BeiGene Ltd., Daiichi Sankyo Co. Ltd., Everest Pharmaceuticals Ltd., GlaxoSmithKline Plc, IMPACT Therapeutics, Jeil Pharmaceuticals Co. Ltd., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Johnson and Johnson, Karyopharm Therapeutics Inc., Merck and Co. Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Repare Therapeutics Inc., Teva Pharmaceutical Industries Ltd., and Zai Lab Ltd..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is extensive ongoing research.'
According to the report, one of the major drivers for this market is the expanded application of PARP inhibitors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Allarity Therapeutics Inc.
- Artios Pharma
- AstraZeneca Plc
- Bayer AG
- BeiGene Ltd.
- Daiichi Sankyo Co. Ltd.
- Everest Pharmaceuticals Ltd.
- GlaxoSmithKline Plc
- IMPACT Therapeutics
- Jeil Pharmaceuticals Co. Ltd.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Johnson and Johnson
- Karyopharm Therapeutics Inc.
- Merck and Co. Inc.
- Ono Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Repare Therapeutics Inc.
- Teva Pharmaceutical Industries Ltd.
- Zai Lab Ltd.
